513 results on '"Cooper, Mark E"'
Search Results
2. Endothelial NOX5 Obliterates the Reno-Protective Effect of Nox4 Deletion by Promoting Renal Fibrosis via Activation of EMT and ROS-Sensitive Pathways in Diabetes
3. Urine Albumin-Creatinine Ratio Variability in People With Type 2 Diabetes: Clinical and Research Implications
4. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin
5. YB-1: the Jekyll and Hyde of kidney disease?
6. Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?
7. Deep multi-omic profiling reveals extensive mitochondrial remodeling driven by glycemia in early diabetic kidney disease
8. Novel pharmacological interventions for diabetic kidney disease
9. Circulating epigenomic biomarkers correspond with kidney disease susceptibility in high-risk populations with type 2 diabetes mellitus
10. Clinical Trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years
11. An Engineered Nanosugar Enables Rapid and Sustained Glucose‐Responsive Insulin Delivery in Diabetic Mice (Adv. Mater. 21/2023)
12. SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
13. Supplementary Table 1 from The Association of High-Density Lipoprotein Cholesterol with Cancer Incidence in Type II Diabetes: A Case of Reverse Causality?
14. Supplementary Table 1 from The Association of High-Density Lipoprotein Cholesterol with Cancer Incidence in Type II Diabetes: A Case of Reverse Causality?
15. An Engineered Nanosugar Enables Rapid and Sustained Glucose‐Responsive Insulin Delivery in Diabetic Mice
16. Reduced methylation correlates with diabetic nephropathy risk in type 1 diabetes
17. The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes
18. Pyridoxamine prevents increased atherosclerosis by intermittent methylglyoxal spikes in the aortic arches of ApoE-/- mice
19. Whether Renal Pathology Is an Independent Predictor for End-Stage Renal Disease in Diabetic Kidney Disease Patients with Nephrotic Range Proteinuria: A Biopsy-Based Study
20. Treatment of Type 2 Diabetes With GLP-1 Receptor Agonists Among Patients With CKD
21. Clinical and Pathological Features of Chinese Patients with Type 2 Diabetes, Biopsy-Proven Diabetic Kidney Disease, and Rapid eGFR Decline
22. Elevated Fasting Blood Glucose Levels Are Associated with Worse Clinical Outcomes in COVID-19 Patients Than in Pneumonia Patients with Bacterial Infections
23. Renal fibrosis as a hallmark of diabetic kidney disease: potential role of targeting transforming growth factor-beta (TGF-β) and related molecules
24. Inhibition of pancreatic EZH2 restores progenitor insulin in T1D donor
25. 437-P: NOX5 in Human Peripheral Blood Mononuclear Cells Is a Potential Biomarker for Unstable Diabetic Vascular Disease
26. Low- and middle-income countries demonstrate rapid growth of type 2 diabetes: an analysis based on Global Burden of Disease 1990–2019 data
27. Recent advances in the pharmacotherapeutic management of diabetic kidney disease
28. Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney disease
29. Independent of Renox, NOX5 Promotes Renal Inflammation and Fibrosis in Diabetes by Activating ROS-sensitive Pathways
30. Independent of Renox, NOX5 Promotes Renal Inflammation and Fibrosis in Diabetes by Activating ROS-sensitive Pathways
31. Independent of Renox, NOX5 Promotes Renal Inflammation and Fibrosis in Diabetes by Activating ROS-Sensitive Pathways
32. Contributors
33. Complications of Diabetes Mellitus
34. Addition of glomerular lesion severity improves the value of anemia status for the prediction of renal outcomes in Chinese patients with type 2 diabetes
35. Prognostic value of metabolic syndrome in renal structural changes in type 2 diabetes
36. Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease
37. High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 Outcome
38. Association between serum uric acid and renal outcome in patients with biopsy-confirmed diabetic nephropathy
39. The Discordance Between the Renal Histopathology and Clinical Presentation of Diabetic Nephropathy Calls for Novel Approaches for the Prediction and Monitoring of Kidney Failure in Diabetes
40. Advances in clinical research in chronic kidney disease
41. Diabetic kidney disease, a potentially serious issue resulting from collision of the coronavirus disease 2019 and diabetes global pandemics
42. Potential cardiorenal benefits of efpeglenatide in diabetes
43. Sex Differences in Biopsy-Confirmed Diabetic Kidney Disease
44. Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function
45. Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial
46. Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A4Mimetics (QNX-sLXms)
47. Key profibrotic and pro-inflammatory pathways in the pathogenesis of diabetic kidney disease
48. Targeting Methylglyoxal in Diabetic Kidney Disease Using the Mitochondria-Targeted Compound MitoGamide
49. Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes
50. Processed foods drive intestinal barrier permeability and microvascular diseases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.